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Abstract
Objective: The present study was done to investigate the effects of supersensi-
tive PSA-controlled inductive treatment on positive margins, detection of
tumor and epithelial cells in bone marrow of 101 patients with untreated and
clinically localized prostatic carcinoma (cT1–3N0M0). Methods: Hormonal
treatment was given until PSA (DPD Immulite® third-generation assay)
reached !0.1 ng/ml or the nadir value, as shown by two consecutive measure-
ments at monthly intervals. Results: The resultant median duration of treat-
ment was 6 months (range 3–22). Ninety-three (93%) of our patients reached a
PSA value !0.1 ng/ml. The nadir of 6 patients (6%) was between 0.1 and
0.3 ng/ml, and it remained 10.3 ng/ml in only 1 case. Of the 101 patients, 82
had a measurable hypoic lesion on initial transrectal ultrasound. 84% of these
became smaller, 7.5% remained unchanged and 8.5% increased. Of the 101
prostatectomy specimens, 20 (20%) were margin-positive. The incidence of
affected margins was relatively high (35% from 55 patients) with cT3 tumors,
but almost negligible (2% from 46 patients) in cT1–2 tumor. Our pathologists,
despite their great experience in evaluating hormonally treated prostates
(1500 cases) and using immunohistochemical staining, were unable to detect
carcinoma in 15 (15%) specimens. Whereas only 2 (4%) of the 55 cT3 speci-
mens were without detectable tumor, this incidence rised to 28% (13 of 46
prostates) in patients with cT1–2 tumors. Of the initial 29 patients with epi-
thelial cells in bone marrow, only 4 (14%) remained positive after controlled
induction and all of them had fewer cells than before. Conclusion: Endocrine
induction controlled by a supersensitive PSA assay and continued until reach-
ing PSA nadir is highly effective in clearing surgical margins and eliminating
tumor cells from bone marrow. It seems to be clearly superior to the conven-
tional 3 months of pretreatment at least in cT1–2 tumors in respect to surgical
margins and detectability of tumor in the resected prostate. A definitive state-
ment about the value of endocrine induction can only be given by prospective
randomized studies, with optimal drugs, doses and treatment time. But the
conventional 3 months of pretreatment are far from exploiting the possibili-
ties of this therapeutic option.
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Introduction
Radical prostatectomy cures clinically localized pros-
tatic cancer if it succeeds in removing all malignant cells.
Unfortunately, in many cases, the operation is performed
too late to achieve this goal. As a consequence, local
tumor rests and/or systemic micrometastases persist and
may decide the fate of many patients. Positive margins
point to local recurrence and epithelial cells in bone mar-
row to micrometastases. Of course they do not always
imply the same end result. Nevertheless, it appears highly
desirable to reduce the incidence of both. Whether this
will result in better survival remains to be seen. However,
prostatic carcinoma would be a very unusual tumor if it
did not.
Several studies show that the incidence of positive
margins can be reduced by 3 months of endocrine pre-
treatment. However, this rigid time schedule is arbitrary
and does not take into account the many peculiarities of
the disease. Among patients treated by intermittend an-
drogen suppression, Goldenberg et al. [1] observed that
PSA nadir and maximal soft tissue metastatic regression
were not reached until 8 months in many patients. At the
1995 AUA meeting the same group [2] claimed: ‘Maxi-
mal biochemical and pathological downstaging requires
8 months of neoadjuvant hormonal therapy prior to radi-
cal prostatectomy.’ On the other side, in a more recent
paper [3], these authors stated that among 50 patients
with clinically confined prostate cancer treated for
8 months, 34% reached the PSA nadir at 3 months, 60%
at 5 and 84% (not 100%) at 8 months. These data strongly
suggest that the duration of inductive treatment should be
individualized and not schematized to achieve maximal
effectiveness and minimal costs.
In the present study, 101 patients with clinically local-
ized prostate cancer were treated by complete androgen
deprivation and monitored with a supersensitive PSA
assay until PSA nadir or a value !0.1 ng/ml was reached,
as shown by two consecutive PSA measurements at
monthly intervals. We present the effects of this more
individualized and controlled treatment on positive mar-
gins, detectability of tumor in the prostatectomy speci-
men and tumor cells in bone marrow.
Patients and Methods
One hundred and one patients with untreated and clinically local-
ized prostatic carcinoma (cT1–3N0M0) were submitted to neoadju-
vant complete androgen deprivation treatment. cT stage was deter-
mined by digital rectal examination (DRE). Laparoscopic lymphad-
enectomy and bone scans to exclude metastases were done if the ini-
tial PSA value exceeded 10 ng/ml. Additionally, all patients had a
thorough transrectal ultrasonographic examination (TRUS) with
measurement of the prostate and if possible also the ‘tumor volume’.
For the latter, the three major perpendicular diameters of eventual
hypoechoic areas were measured and volume calculated according to
the prolated ellipsoid formula. Furthermore, 86 patients had a bilat-
eral, iliac bone marrow biopsy initially for detection of epithelial
cells. Of these, 75 were rebiopsied at the time of radical prostatecto-
my. After these initial examinations and after obtaining informed
consent, endocrine treatment with flutamide (Fugerel® 3 ! 250 mg/
day) and leuproreline acetate (Enantone® 3.75 mg monthly) was ini-
tiated and continued until the day before operation. Patients were
controlled at roughly monthly intervals in a special prostate cancer
clinic during endocrine treatment. At each visit, PSA, DRE and
TRUS were repeated. If PSA did not fall on two consecutive, month-
ly examinations or was found to be !0.1 ng/ml twice, the nadir was
considered to be reached and the patient submitted for radical pros-
tatectomy.
PSA determinations were done by the DPD Immulite® third-gen-
eration assay with an analytical sensitivity of !0.003 ng/ml. For
TRUS we used a 7.5-MHz multiplanar probe (Kraetz®). Epithelial
cells in bone marrow were detected by immunochemistry using the
monoclonal antibody CK2, to epithelial cytokeratin component 18
(CK18). Technical details have been published elsewhere [4]. Radi-
cal prostatectomy was done in the majority of patients by the trans-
coccygeal route. Specimens were inked, then fixed in formalin 10%
and cut in 3-mm-thick blocks, according to the Stanford protocol.
Routine histopathology was done on HE-stained slides. Additional
immunohistochemical staining with antibodies to high molecular
cytokeratin (M903) and pancytokeratin (Lu 5) were carried out in
every case if no tumor was detected on routine examination and if
HE was considered insufficient concerning infiltration of the mar-
gins.
Results
Patient Characteristics. Forty-six patients had a clini-
cal T1 (25) or T2 (21) tumor and 55 were cT3 cases. Only
82 (82%) had measurable hypoechoic lesions on TRUS.
They were smaller in cT1–2 (0.2–3.3, median 0.77 ml)
than in cT3 cases (0.14–10.7, median 1.39 ml). The me-
dian of initial PSA was 12.85 ng/ml (range 0.5–208). As
expected, it was higher in cT3 tumors (14.7) than in lower
stages (11.2). Clinical T1+2 tumors were on the whole
(72%) well differentiated (^G2a). On the contrary, cT3
cases were predominantly (73%) high-graded (6G2b).
Eighty-six of the 101 patients had a pretherapeutic bone
marrow biopsy. Epithelial cells were found in 29 (34%).
This was more frequent (43%) in cT3 than in cT1–2 can-
cers (24%), in patients with hypoechoic lesions over 2 ml
(50%) than with smaller foci (29%), and with high-grade
(32%) than low-grade tumors (26%).
Duration of Treatment. Median duration of controlled,
inductive treatment was 6 months and it varied between
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Fig. 1. Duration of treatment (see text
for details).
Table 1. Margins of 101 prostatectomy specimens after con-
trolled induction in relation to the initial cT stage
cT stage Margin-positive Margin-negative Total
1 = 2% 45 = 98% 46 = 100%
T3 19 = 35% 36 = 65% 55 = 100%
T1+T2+T3 20 = 20% 81 = 80% 101 = 100%
Table 2. Frequency of no tumor detectable (pT0) in 101 prosta-
tectomy specimens after controlled induction, in relation to the ini-
tial cT stage
cT stage Patients No tumor detectable (pT0)
n %
46 13 28
T3 55 2 4
T1+T2+T3 101 15 15
3 and 22 months. After 3 months only 3% of our patients
reached the PSA nadir, and even at 8 months 25% did not
(fig. 1). There was no significant difference in treatment
time beween cT1+2 vs. cT3, high-grade vs. low-grade
tumors and patients with hypoechoic lesions 12 ml vs.
!2 ml.
Effect on PSA. Ninety-three (93%) of our 101 patients
reached a PSA nadir of 0.1 ng/ml or below. The nadir of
the remaining patients was between 0.1 and 0.3 ng/ml in 7
(7%) and over 0.3 ng/ml in 1 (1%).
Effect on Hypoechoic Lesions. Of the measurable hy-
poechoic lesions in 82 patients, 69 (84%) became smaller,
6 (7.5%) remained unchanged and 7 (8.5%) increased.
Whereas the median initial volume of hypoechoic lesions
was 1.13 ml after induction it was 0.46 ml.
Effect on Epithelial Cells in Bone Marrow. Of the 29
patients with epithelial cells in bone marrow before induc-
tive treatment, only 4 (14%) remained positive thereafter,
and all of these 4 patients had fewer cells than initially.
Effect on Specimen Margins. Of our 101 patients, 20
(20%) had positive and 80 (80%) negative margins (ta-
ble 1). The rate of negative margins was extremely low in
the group of 46 patients with clinical T1 and T2 tumors
(2%) in comparison to the 55 T3 cases (35%).
Effect on Tumor Detection. In 15 (15%) of the 101
prostatectomy specimens, the pathologist was unable to
detect carcinoma (table 2). This was rare in cT3 cases (2 =
4%) but surprisingly frequent with cT1+2 tumors (13 =
28%).
D
ow
nl
oa
de
d 
by
: 
UB
 d
er
 L
M
U 
M
ün
ch
en
   
   
   
   
   
   
   
   
   
   
   
   
 
12
9.
18
7.
25
4.
47
 - 
8/
12
/2
01
3 
12
:0
7:
10
 P
M
Supersensitive PSA-Monitored
Neoadjuvant Hormone Treatment of
Prostate Cancer
Eur Urol 1998;34:318–324 321
Discussion
Duration of Treatment
Inductive treatment of prostatic carcinoma was inau-
gurated by Vallet [5] in 1944. Since then, the proposed
duration and means of hormonal manipulation has varied
widely. The majority [6–12] of recent studies referred to
3 months of pretreatment. On the other hand, already
some of the pioneers of neoadjuvant therapy adminis-
tered a more individualized and prolonged schedule. In
1949, Parlow and Scott [13] pretreated their patients dur-
ing 3, 4, 6, 12, 15, 24 and 36 months respectively, moni-
toring response by DRE. Recently the Vancouver group
[1–3] argued again in favor of a more prolonged induc-
tion, but they also used a prefixed time schedule of
8 months. Their results on margins were clearly better
than the data reported from 3-month series. The present
study confirms the general superiority of a longer treat-
ment, but it shows on the one hand that not all patients
need 8 months, and on the other that a few must be
treated considerably longer.
Effect on PSA
PSA has been shown to be a very sensitive tool for eval-
uation of primary treatment in patients with prostatic car-
cinoma. The tumor is responding as long as PSA is falling
and progressing when it rises [14]. However, progression
may also (very seldom) occur without an increasing PSA.
All of our patients showed a decrease in serum PSA after the
beginning of neoadjuvant hormonal therapy. Thus, all of
them were responders. But the response shown by declining
PSA values may be due to downregulation of PSA ex-
pression and shrinking of PSA-producing tissues (specially
normal prostate and prostatic carcinoma). The primary
goal of neoadjuvant treatment is however reduction of
tumor mass to enhance the chance of eradication by radical
prostatectomy. In view of the different reasons why PSA
decreases under endocrine treatment, it is not surprising
that the decline of PSA is not proportional to the reduction
of tumor burden. Gleave et al. [3] called attention to the bi-
phasic slope of PSA decrease: a precipitous fall specially
during the first, but also during the second and third month
and a much more gradual, subsequent decrease until the
nadir is reached. It is tempting to speculate that phase one is
predominantly due to downregulation of PSA expression,
whereas during the second phase, mass reduction of PSA-
producing tissues prevails. The assumption that tumor
shrinking at least continues after first phase PSA decline is
supported by the effects of prolonged treatment on pro-
statectomy specimens (margins and tumor detectability).
The analytical sensitivity of commonly available PSA
assays limits their usefulness as indicators of response
precisely where they are most needed: in the second phase
of the slope or !0.3 ng/ml. In recent years however, sever-
al PSA assays with lower analytical detection limits have
been developed. In the present study the DPD Immulite®
third-generation PSA assay was employed. It claims an
analytical detection limit of !0.003 ng/ml and a working
range of 0.01–20 ng/ml [15]. With a test of this sensitivity
the slope of declining PSA can be followed far beyond
the limits of conventional assays. We arbitrarily chose
!0.1 ng/ml as an endpoint of pretreatment. However,
probably for many patients this was not the real endpoint
of the PSA slope. Whether continuation of treatment to
the absolute nadir is worthwhile has yet to be shown. Our
results suggest that this indeed may be the case, at least for
patients with cT3 tumors.
Effect on Hypoechoic Lesions
Carcinomatous lesions of the prostate are predomi-
nantly hypoechoic. Despite the fact the many other enti-
ties are also hypoechoic, serial measuring of them may
contribute more specific information about shrinking of
tumors. The fact that the great majority (84%) of hypoe-
choic lesions became smaller by more than 50% gives
additional support to the thesis that the lowering of PSA is
not only caused by downregulation of PSA expression or
downsizing of the normal prostate, but also by a real and
considerable reduction of the tumor mass itself. This con-
firms data published by Pinault et al. [16] in a smaller
series.
Effect on Epithelial Cells in Bone Marrow
Extrinsic cells in bone marrow detected by immunos-
taining with anticytokeratin antibodies are supposed to be
tumor cells. This assumption is supported by the follow-
ing observations: (1) These cells are almost exclusively
found in patients with epithelial tumors and not in
patients without cancer [17]. (2) In patients with prostatic
carcinoma, cytokeratin-positive cells in bone marrow car-
ry the same chromosomal abnormalities (aneusomies) as
the primary tumor [18]. (3) In prostatic cancer patients
these cells may express PSA and PSMA epitopes [19].
(4) Cytokeratin-positive cells in bone marrow show sever-
al tumor-associated characteristics such as increased ex-
pression of oncogenes, downregulation of MHC antigens,
growth in cell culture and SCI mice [20–22]. (5) The
detection of epithelial cells in bone marrow is of prognos-
tic significance in patients with various types of solid epi-
thelial tumors [23, 24, 28]. This, however, has not been
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Gomella et al. [32]
322 Eur Urol 1998;34:318–324 Köllermann/Pantel/Enzmann/Feek/
Köllermann/Kossiwakis/Kaulfuss/Martell/
Spitz
Table 3. Frequency of positive margins
in untreated und conventionally pretreated
patients with clinically localized prostatic
carcinoma
Authors Untreated
patients margin +, %
Pretreated
patients margin +, %
92 36 92 11
Pedersen et al. [7] 54 46 60 24
Soloway et al. [8] 137 47 144 17
Labrie et al. [9] 71 34 90 8
Klotz et al. [10] 91 65 101 28
Bellavance et al. [11] 275 39 165 24
Debruyne et al. [12] 154 44 136 26
Van Poppel et al. [36] 62 46 65 32
Total/average 936 45 853 21
Table 4. Margin positivity after conventional pretreatment of
patients with cT1–2 tumors in comparison with our results after con-
trolled induction
Authors cT stage Patients Margin +, %
2b 144 17
Klotz et al. [10] 1–2 101 28
Bellavance et al. [11] 1–2 165 24
Debruyne et al. [12] 2 68 13
Fair et al. [6] 1–2 111 11
Van Poppel et al. [36] 2 36 19
Labrie et al. [9] 1–2 75 8
Total/average 700 17
Ipse 1–2 46 2
Table 5. Margin positivity after more prolonged and controlled
pretreatment of patients with cT1–2 tumors
Authors cT stage Patients Margin +, %
? 40 6
Gleave et al. [3] T1–2 44 4
Ipse T1–2 46 2
clearly demonstrated for patients with prostatic carcino-
ma.
The results of the present study, which found epithelial
cells to be more frequent in bone marrow of patients with
large and undifferentiated than with small and well-differ-
entiated cancers, reinforce the concept of their tumorous
Table 6. Margin positivity after conventional pretreatment of
patients with cT3 tumors in comparison with our results after con-
trolled induction
Author cT stage Patients Margin +, %
cT3 21 43
Debruyne et al. [12] cT3 61 44
Fair et al. [6] cT3 27 26
Abbas et al. [33] cT3 8 25
Solomon et al. [34] cT3 8 37
Cher et al. [35] cT3 26 31
Van Poppel et al. [36]
Labrie et al. [9] cT3 15 6
Total/average 195 33
Ipse cT3 55 35
nature. It is also supported by their marked reduction
after neoadjuvant therapy. But all this does not mean that
the finding of these cells in bone marrow of patients with
seemingly localized prostatic carcinoma is tantamount to
the presence of micrometastases, which sooner or later
grow up to overt filiae. At least some of them may disap-
pear by mechanisms of self-defense or lack of vitality.
This is supported by the following facts: (1) Using PSA
RT-PCR in bone marrow, Melchior et al. [25] found a
positive reaction in 62% of 69 patients with clinically
localized prostatic cancer. This is an incidence well above
the reported relapse rates. (2) The same group performed
bone marrow rebiopsies on 24 formerly positive patients
after radical prostatectomy. Only 6 (25%) had a persis-
tently positive RT-PCR.
All we know is that tumor cells are an absolute prereq-
uisite for the development of metastases. But how often
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this occurs and if the risk of it is reliably reduced by elimi-
nating or diminishing them is open to question and must
be further investigated. At least one of the criticisms of
neoadjuvant treatment, namely that the tumor may me-
tastasize in the meantime, seems highly improbable in
view of our results.
Effects on Specimen Margins
Positive surgical margins are associated with an in-
creased risk of relapse [26]. Their incidence in patients
without pretreatment varies from 16 to 65% [27]. Reduc-
ing margin positivity may therefore improve the results of
radical prostatectomy. Various studies showed that endo-
crine treatment is able to decrease the frequency of
affected margins (table 3). Drugs and doses employed by
these authors varied, but all of them (except Bellavance et
al. [11] who used a more prolonged pretreatment for some
of their patients) used a rigid time schedule of approxi-
mately 3 months (van Poppel et al. [36], 6 weeks). Com-
paring their results with ours (table 1) shows: the overall
incidence of positive margins is almost the same (21 vs.
20%), suggesting no difference between treatment modal-
ities. But this is easily explained by patient selection.
Whereas the vast majority (88%) of the patients compiled
in table 3 had cT1–2 tumors, only 46% of ours belonged
to this category. The remaining majority of 54% were cT3
cases. In table 4 we extracted the cT1–2 patients from
table 3 (where this was possible). Comparing now the
results of standard pretreatment in cT1–2 tumors with
ours of the same stage shows a clear advantage of con-
trolled induction: 17 vs. 2% positive margins. This very
low incidence of margin positivity in our admittedly small
series of cT1–2 tumors is confirmed by the results of oth-
ers, who also employed longer pretreatment times (ta-
ble 5).
Comparing however the results of standard pretreat-
ment in cT3 cases with ours of the same stage shows no
advantage of controlled induction: 33 vs. 35% positive
margins (table 6). But considering on the one hand the
very small number of cases in the majority of the series
compiled in table 6, with widely diverging results and the
even smaller amount of data from more prolonged treat-
ment schedules on the other, it seems too early for final
conclusions. This item clearly deserves further studies.
Effect on Tumor Detection
The most surprising result of the present study was that
after controlled induction, 28% of our patients with initial
cT1–2 tumors had no tumor detected in their prostatecto-
my specimen. In patients with cT3 tumors the incidence
was only 4%. This is not new. It was first reported by
Gutierrez [28], one of the pioneers of inductive treatment,
in 1949. Thereafter, many additional cases were more or
less casually mentioned in multiple publications.
There are various reasons why an initially diagnosed
carcinoma may be missed in the resected prostate after
inductive treatment: (1) The initial carcinoma was very
small and despite its unaltered persistence it is simply
overlooked. (2) The tumor suffered marked regressive
changes and cannot be identified despite its persistence.
(3) The tumor was really eliminated by inductive treat-
ment. We believe that none of these reasons is explicatory
to all of our cases, but all of them may be contributory.
Conclusions
Biochemical relapse occurs in 35–40% of the patients
submitted to radical prostatectomy for a seemingly resect-
able carcinoma. This rather high failure rate is due to car-
cinomatous cells left behind locally and/or elsewhere. Pos-
itive margins and epithelial cells in bone marrow are sus-
pected to be forerunners of relapse. A series of prospective
and randomized studies showed that margin positivity
can be reduced by endocrine pretreatment of 6–12 weeks’
duration. Nevertheless, at 2 and 3 years the recurrence
rate could not be improved with these regimens [29–31].
Recently a few studies [1–3, 11] presented evidence that
longer pretreatment (e.g. 8 months) is more effective on
margins than conventional schedules. This is roughly con-
firmed by the present study at least in T1–2 cases. In addi-
tion, we found a surprisingly high rate of no tumors
detected in our prostatectomy specimens and a marked
reduction of epithelial cells in bone marrow. In view of
these results we are convinced that the conventional
3 months of pretreatment do not exploit the possibilities
inherent to neoadjuvant hormonal therapy, at least in the
majority of patients. As with any other therapy, a mean-
ingful evaluation presupposes adequate treatment times.
Our data suggest that this cannot and in consequence
should not be fixed ad hoc for all patients and tumors,
rather it must be individually searched for by PSA moni-
toring with an assay of high sensitivity.
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